Inotuzumab Ozogamicin

Last Updated: 11/08/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 574 publications

Advances in the treatment of relapsed or refractory acute lymphoblastic leukemia

Advances in the treatment of relapsed or refractory acute lymphoblastic leukemia

Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology

Published: October 28, 2026

Successful Engraftment Following Blinatumomab and Donor-Derived Buffy Coat Infusion in a Patient With Relapsed B-cell Acute Lymphoblastic Leukemia and High-Level Donor-Specific Anti-HLA Antibodies: A Case Report.

Successful Engraftment Following Blinatumomab and Donor-Derived Buffy Coat Infusion in a Patient With Relapsed B-cell Acute Lymphoblastic Leukemia and High-Level Donor-Specific Anti-HLA Antibodies: A Case Report.

Journal: Cureus

Published: August 27, 2026

Dose optimization of single-agent inotuzumab ozogamicin in adults with relapsed/refractory acute lymphoblastic leukemia.

Dose optimization of single-agent inotuzumab ozogamicin in adults with relapsed/refractory acute lymphoblastic leukemia.

Journal: Leukemia & lymphoma

Published: August 18, 2026

Response-adapted inotuzumab ozogamicin in paediatric first-relapse B-cell acute lymphoblastic leukaemia - Authors' reply.

Response-adapted inotuzumab ozogamicin in paediatric first-relapse B-cell acute lymphoblastic leukaemia - Authors' reply.

Journal: The Lancet. Haematology

Published: August 10, 2026

A real-world pharmacovigilance analysis of cardiac adverse events associated with newer antibody-drug conjugates for hematological malignancies in adults: A disproportionality analysis from FDA adverse event reporting system database.

A real-world pharmacovigilance analysis of cardiac adverse events associated with newer antibody-drug conjugates for hematological malignancies in adults: A disproportionality analysis from FDA adverse event reporting system database.

Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

Published: July 31, 2026

Tripping the switch: p38 inhibition unlocks venetoclax and inotuzumab ozogamicin synergy.

Tripping the switch: p38 inhibition unlocks venetoclax and inotuzumab ozogamicin synergy.

Journal: Haematologica

Published: July 15, 2026

The 21st International ``Ponte di Legno'' Childhood Acute Lymphoblastic Leukemia Workshop Report: Progress and Emerging Opportunities.

The 21st International ``Ponte di Legno'' Childhood Acute Lymphoblastic Leukemia Workshop Report: Progress and Emerging Opportunities.

Journal: Clinical lymphoma, myeloma & leukemia

Published: July 05, 2026

Response-adapted inotuzumab ozogamicin in paediatric first-relapse B-cell acute lymphoblastic leukaemia.

Response-adapted inotuzumab ozogamicin in paediatric first-relapse B-cell acute lymphoblastic leukaemia.

Journal: The Lancet. Haematology

Published: July 01, 2026

A real-world multi-institution experience of standard versus alternative dosing regimens of inotuzumab ozogamicin for relapsed/refractory paediatric B-cell acute lymphoblastic leukaemia.

A real-world multi-institution experience of standard versus alternative dosing regimens of inotuzumab ozogamicin for relapsed/refractory paediatric B-cell acute lymphoblastic leukaemia.

Journal: British journal of haematology

Published: June 29, 2026

Venetoclax plus Inotuzumab Ozogamicin for Relapsed and Refractory Acute Lymphoblastic Leukemia.

Venetoclax plus Inotuzumab Ozogamicin for Relapsed and Refractory Acute Lymphoblastic Leukemia.

Journal: Blood

Published: June 23, 2026

Timing of Allogeneic Hematopoietic Cell Transplantation after Inotuzumab Ozogamicin Influences Sinusoidal Obstruction Syndrome and Survival in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia.

Timing of Allogeneic Hematopoietic Cell Transplantation after Inotuzumab Ozogamicin Influences Sinusoidal Obstruction Syndrome and Survival in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia.

Journal: Transplantation and cellular therapy

Published: June 15, 2026

Breaching the Blood-Brain Barrier: Evolving Strategies for Central Nervous System Disease in Adult Acute Lymphoblastic Leukemia.

Breaching the Blood-Brain Barrier: Evolving Strategies for Central Nervous System Disease in Adult Acute Lymphoblastic Leukemia.

Journal: Current hematologic malignancy reports

Published: June 12, 2026

Showing 1-12 of 574

Last Updated: 11/08/2026